Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.

@article{Nuzzo2008WeeklyDV,
  title={Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.},
  author={Francesco Nuzzo and Alessandro Morabito and Ermelinda De Maio and Francesca Di Rella and Adriano Gravina and Vincenzo Labonia and Gabriella Landi and Carmen Pacilio and Maria Carmela Piccirillo and Emanuela Rossi and G D'aiuto and Renato Thomas and Stefania Gori and Mariantonietta Colozza and Sabino De Placido and Rossella Lauria and Giuseppe Signoriello and Ciro Gallo and Francesco Perrone and Andrea de Matteis},
  journal={Critical reviews in oncology/hematology},
  year={2008},
  volume={66 2},
  pages={171-80}
}
Within an ongoing multicentre phase 3 randomised trial (ELDA, cancertrials.gov ID: NCT00331097), early breast cancer patients, 65-79 years old, with average to high risk of recurrence, are randomly assigned to receive CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1-8) or docetaxel (35 mg/m2 days 1-8-15), every 4 weeks. Here we report an unplanned safety analysis prompted by an amendment introducing creatinine clearance as a tool to adjust methotrexate dose… CONTINUE READING